US 10,888,544 B2
Methods for treating Gaucher disease
Jing Li, Bridgewater, NJ (US); M. Judith Peterschmitt, Watertown, MA (US); Vanaja Kanamaluru, Bridgewater, NJ (US); Jun Chen, Bridgewater, NJ (US); Sebastiaan J. M. Gaemers, Naarden (NL); and Dan Rudin, Cambridge, MA (US)
Assigned to GENZYME CORPORATION, Cambridge, MA (US)
Filed by Genzyme Corporation, Cambridge, MA (US)
Filed on Dec. 13, 2018, as Appl. No. 16/219,064.
Claims priority of provisional application 62/599,467, filed on Dec. 15, 2017.
Prior Publication US 2019/0183844 A1, Jun. 20, 2019
Int. Cl. A61K 31/343 (2006.01); A61K 31/496 (2006.01); A61K 31/15 (2006.01); A61K 45/06 (2006.01); A61K 31/138 (2006.01); A61K 31/427 (2006.01); A61P 3/00 (2006.01); A61K 31/4422 (2006.01); A61K 31/381 (2006.01); A61K 31/4025 (2006.01); A61P 1/16 (2006.01); A61P 13/12 (2006.01)
CPC A61K 31/343 (2013.01) [A61K 31/138 (2013.01); A61K 31/15 (2013.01); A61K 31/381 (2013.01); A61K 31/4025 (2013.01); A61K 31/427 (2013.01); A61K 31/4422 (2013.01); A61K 31/496 (2013.01); A61K 45/06 (2013.01); A61P 1/16 (2018.01); A61P 3/00 (2018.01); A61P 13/12 (2018.01)] 9 Claims
 
1. A method of treating Gaucher disease comprising administering to a patient in need thereof an adjusted effective amount of eliglustat, or a pharmaceutically acceptable salt thereof, wherein said patient is an extensive CYP2D6 metabolizer with mild hepatic impairment and wherein said patient is concurrently taking a drug that is strong or moderate CYP3A inhibitor.